Prostate Cancer

I knew virtually nothing about cancer until I became a caregiver for my aunt Carolyn, who died of colorectal cancer in 2000.

A genitourinary oncologist provides insights on the treatment decision-making process and the roles of guidelines for prostate cancer.

An experienced public health and cancer researcher offers advice to patients newly diagnosed with prostate cancer and discusses barriers to access to care.

Rashid K. Sayyid, MD, MSc, describes the staging and risk stratification process for patients with prostate cancer and their effect on prognosis.

Reginald Tucker-Seeley, MA, ScM, ScD, gives an overview of the screening and diagnosis process of prostate cancer.

Treatments intended to reduce biochemical recurrence in patients with prostate cancer may not improve long-term survival, recent research showed.

In honor of Prostate Cancer Awareness Month, we looked back at some of our most viewed and significant prostate cancer content from the summer of 2023.

Here’s a look back at the therapies for solid cancers that gained FDA approval this summer.

The FDA has granted a priority review for the evaluation of Xtandi as a treatment for patients with non-metastatic castration-sensitive prostate cancer.

When asked for recommended treatments for certain types of cancer, ChatGPT missed the mark about one-third of the time, research showed.

Clinical insights on the typical presentation of prostate cancer and how the disease is diagnosed.

Alicia Morgans, MD, MPH, reviews the incidence of prostate cancer and risk factors associated with the disease.

Treatment with Cabometyx plus Tecentriq improved progression-free survival for patients with metastatic castration-resistant prostate cancer.

New PSMA PET/CT can detect signs of prostate cancer within elderly patients without the need of a biopsy.

The day before I was diagnosed with prostate cancer, I didn’t pay enough attention to my brother-in-law’s arduous journey with Parkinson’s disease.

Akeega, the first dual action tablet with a PARP inhibitor and abiraterone acetate, was approved for the treatment of patients with suspected or confirmed BRCA-positive metastatic castration-resistant prostate cancer.

When Black individuals learned about prostate cancer from Black doctors, they were more likely to trust the information, recent research showed.

The Food and Drug Administration is reportedly expediting the review of Ambrx’s treatment for patients with metastatic, castration-resistant prostate cancer that has displayed promising early trial results.

Being told to write was the best advice I could have ever received.

Artificial intelligence was used to develop a predictive biomarker to identify patients with intermediate-risk prostate cancer who would benefit from adding androgen deprivation therapy to radiotherapy.

When it came to content on the mental health effects of prostate cancer, a review of YouTube videos found the results to be lacking.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

The combination of Talzenna and Xtandi was approved for the treatment of adults with HRR gene-mutated metastatic castration-resistant prostate cancer.

Here’s an overview of the new cancer regimens that gained Food and Drug Administration (FDA) approval in the spring of this year.

From Colin McFarlane and John Homme opening up about their cancer diagnoses to Pope Francis visiting a pediatric oncology ward, here’s what’s happening in the cancer space this week.

I transformed my mindset to maximize healing before, during and after prostate cancer treatment.

Side effects such as anemia and other blood-related events were resolved with dose reductions and/or supportive care in men with metastatic castration-resistant prostate cancer.

Treating patients with metastatic castration-resistant prostate cancer with radium-223 also allowed patients to receive subsequent therapies such as chemotherapy.

Lynparza plus abiraterone was approved by the FDA for the treatment of patients with deleterious or suspected BRCA-mutated metastatic castration-resistant prostate cancer.

The approval of Posluma will help clinicians determine the extent of disease in men with prostate cancer and possible management options.